Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
The logic
In December, the FDA approved a label update for Yescarta (axicabtagene ciloleucel) to include the overall survival (OS) primary analysis from the landmark Phase 3 ZUMA-7 study showing a statistically significant improvement for Yescarta in OS versus standard of care (SOC) as second-line treatment with curative intent for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) within 12 months of completion of first-line therapy
Community Corner Zarett Rehab Maximizing the Benefits of GLP-1: Why Exercise is the Missing Link in Weight Loss Quality From a Brand Partner: The rise of GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro has revolutionized weight management
Potential Benefits for Optic Nerve Health While there is still a lot of research that needs to be done, the idea of semaglutide protecting the optic nerve is promising
US$ 28.17
US$ 28.53
US$ 23.73
US$ 29.26
US$ 20.91
US$ 21.42
US$ 27.13
US$ 21.14
US$ 27.68
US$ 22.96
US$ 20.59
US$ 22.81
